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An atom efficient synthesis of tamoxifen†
Dorus Heijnen,‡ Milan van Zuijlen,‡ Filippo Tosi‡ and Ben L. Feringa *
The direct carbolithiation of diphenylacetylenes and their cross-
coupling procedure taking advantage of the intermediate alkenyl-
lithium reagents are presented. By employing our recently
discovered highly active palladium nanoparticle based catalyst, we
were able to couple an alkenyllithium reagent with a high (Z/E)
selectivity (10 : 1) and good yield to give the breast cancer drug
tamoxifen in just 2 steps from commercially available starting
materials and with excellent atom economy and reaction mass
efficiency.
The continuous improvement of synthetic routes towards med-
icinally relevant and/or biologically active compounds has
drawn the attention of synthetic chemists for decades.1 In
order to reduce waste and increase yields and cost efficiency or
to simplify the procedures towards relevant structures, tran-
sition metal catalysis has been a game changer in the field.2
Since the emergence of the Suzuki (B), Stille (Sn), Negishi (Zn)
and Hiyama–Denmark (Si) reactions, the trend in the cross-
coupling methodology3 has been to transmetallate highly
polar (but straightforward to synthesize) organometallic
reagents (RMgX, RLi) to softer nucleophiles in order to gain
stability and functional group tolerance and reduce the overall
sensitivity of the reaction. Despite their major role in our
modern synthetic toolbox, the drawbacks of these additional
synthetic steps are longer reaction times, the production of
stoichiometric (sometimes toxic) waste, and a decrease in cost
efficiency.4 Nonetheless, the direct coupling of organometallic
reagents arising from a deprotonation or umpolung reaction
has shown great advances in recent years.2,5 Since these
reagents have an intrinsically higher reactivity, the corres-
ponding cross-coupling reactions generally require a shorter
reaction time, and can be performed at significantly lower
temperatures.4 As part of our effort to expand the synthetic
application of our recently reported organolithium cross-coup-
ling reactions,5d,f,g,i–k we envisioned the direct carbolithation–
cross coupling to be a very valuable alternative. The carbo-
lithiation of (diphenyl)acetylenes has been well-studied and
has led to several useful applications in the field of synthetic
organic chemistry.6–10 The quenching of the formed nucleo-
philic sp2 vinyllithium reagent with an electrophile provides a
direct approach to substituted diarylalkenes (stilbenes).
Transmetallation of such anions to magnesium, boron, zinc or
even aluminum yields an active cross-coupling partner, but
drastically lowers the atom economy and E-factor.11,12 The
direct cross-coupling of the formed organolithium reagent is
therefore a highly desired synthetic shortcut, but remains
unreported to the best of our knowledge. Tetrasubstituted
alkenes and triphenylethylenes in particular, i.e. tamoxifen,
make up a class of highly potent and valuable drugs with
(potential) application in the treatment of a variety of con-
ditions, including (breast) cancer, dyspareunia and osteoporo-
sis (Fig. 1).13 Structural variations in the triphenylethylene
scaffold are found in the alkyl–ether substituent (mostly con-
sisting of an amine, shown in blue) and para phenylene func-
tionality (shown in red) as well as in the alkyl fragment (shown
in green) on the remaining alkene position.
Fig. 1 Examples of members of the triphenylethylene family of drugs.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c8ob02977f
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Because of its medicinal importance, a plethora of synth-
eses have been described for (Z)-tamoxifen (Fig. 2).15–37
McMurry coupling of two ketones is a well-established method
for the synthesis of (hindered) alkenes, and as such has proven
to be capable of constructing the alkene fragment in tamoxifen
with reagents 1 and 2.21 Alternatively, 1,2-addition to ketone 3
with Grignard reagent 4 followed by elimination yielding an
alkene is a valuable option, however it is common that both
isomers (E/Z) are isolated via this approach.19,24 The transme-
tallation of the lithium intermediate that is the product of car-
bolithation of the corresponding acetylene yields the alkenyl–
boronic acid/ester, or organozinc reagent 5.20,22 The cross-
coupling of these reagents with bromide 6 provides a viable
route towards the final drug. The transmetallation, however,
generates extra synthetic steps and/or stoichiometric waste. We
therefore reasoned that the direct coupling of the alkenyl-
lithium reagent 7, which is obtained upon carbolithiation of
diphenylacetylene, would be an important atom efficient
alternative to these methods.
In order to optimize the sequential synthetic steps, the
carbolithiation of acetylene 8 was optimized separately, and
the product 10 resulting from MeI quenching was subjected to
GC-MS analysis (Table 1). With a high selectivity for the
(Z)-alkenes for several solvents and solvent mixtures being
investigated, we tried to avoid the use of THF (Table 1, entry 1)
due to expected difficulties in the cross-coupling step arising
from unwanted side reactions, such as lithium–halogen
exchange.5b–g,i–l However, toluene/TMEDA mixtures (entry 2) or
other ethereal solvents (entries 3–5) did not prove equally
efficient as the reaction medium compared to THF due to a lower
extent of lithiation and an increased amount of the (E)-alkene.
Attempts to minimize waste production by neat carbolithiation
(except for the solvent of the n-BuLi solution) resulted in mere
recovery of the starting material (entry 6). Reducing the amount
of THF by using a THF–toluene mixture resulted in incomplete
conversion to the carbolithiated intermediate (entry 7). Despite
the attempts to omit THF as the solvent, we found significantly
better results for the carbolithiation in its presence, and therefore
decided to use it as the solvent for further optimization.
Having established the optimized conditions for the carbo-
lithiation, the cross-coupling with 1-bromonaphthalene pro-
vided the test reaction in pursuit of the best catalyst. Our
oxygen activated palladium nanoparticle catalytic system5k
proved to be highly active in the coupling of alkenyllithium 9
and arylbromides (Table 2, entry 1), being only slightly outper-
formed by the commercial Pd-PEPPSI–Ipent complex (entry 4).
Nickel and palladium bisphosphine complexes (Pd-dppf
and Ni-dppp) did not show conversion to the desired product
Table 1 Optimization of carbolithiation of 8
Entry Solvent 1 h Conv.a 2 h Conv.a Selectivitya,b
1 THF 91% 91% 96%
2 Toluene/TMEDAc 32% 32% 75%
3 2-Me-THF 52% 70% 99%
4 MTBE 0% 6% —
5 Ether 0% 4% —
6 Neat 0% 0% —
7 Toluene/THF 3 : 1 48% 65% 96%
Reaction conditions: 1.1 eq. of n-BuLi were added dropwise to a stirred
0.9 M solution of 8 in THF at 0 °C. At the end of the addition, the
reaction mixture was quickly allowed to warm to room temperature
and left to react for 2 h before 1 eq. of MeI was added. a As determined
by GC-MS analysis after MeI quenching. b (Z/E) selectivity determined
by GC-MS analysis. c 1 eq. of TMEDA.
Table 2 Optimization of cross-coupling of 9 with 1-bromonaphthalene
Entry Cat. (5%) Conversion to 11a





Reaction conditions: 2 eq. of alkenyllithium reagent were added over
20 min to a stirred solution of arylbromide and (pre-oxidized) catalyst
in toluene at 35 °C. a As determined by GCMS analysis. (Z/E) > 9 : 1.
Fig. 2 Synthetic approaches to (Z)-tamoxifen.
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(entries 2 and 3), but the nickel carbene complex C15j did
provide the triarylethylene target 11 (entry 5), albeit in a
reduced yield (for further attempts to use different electro-
philes, see the ESI†). In order to see if this cross-coupling
methodology could be applicable for the cross-coupling of
other arylbromides, we decided to test a few further substrates
(Table 3). The cross-coupling methodology proceeds smoothly
with both electron rich arylbromides (R = Me, OMe, entries 1
and 2) and electron poor substrates (R = CF3, entry 3).
Having tested a small variety of catalysts for the cross coup-
ling with different substrates, the optimized conditions were
employed to synthesize the desired pharmaceutical (Z)-tamoxi-
fen via our new methodology. Changing the nucleophile for
the acetylene carbolithiation from n-butyllithium to ethyl-
lithium gave identical results albeit with a slightly longer reac-
tion time. We were pleased to see that the oxygenated Pd
(PtBu3)2 catalyst gave (Z)-tamoxifen in only a slightly lower
yield than with the naphthalene test substrate, but with very
good (Z/E) selectivity (Table 4, entry 1, (Z/E) > 9 : 1). On pursu-
ing a cheaper catalyst, with a more abundant metal, the
attempted nickel complex gave only small amounts of the
desired product (entry 2).
Much to our surprise, our “working horse” catalyst Pd-
PEPPSI Ipent5g,i was completely inactive in the cross-coupling
with the bromophenyl-aminoether electrophile 6 (Table 4,
entry 3), whereas it proved to be the most active catalyst with
the previously tested 1-bromonaphthalene electrophile
(Table 2, entry 4). The chelating effect of the amino–ether
moiety onto the metal center, overcrowding the palladium,
might play a role making the catalyst inactive. Other dimeric
palladium phosphine complexes, which have recently been
shown to be active in related cross-coupling reactions, were
also tested,5h,k and were found to have very similar reactivity
compared to the catalyst used in entry 1. Being the cheapest of
the three related structures (entries 1, 5 and 6), we decided to
proceed our investigation with the bis(tri-tert-butylphosphine)
palladium complex. The results of further optimization are
shown in Table 5. Varying the temperature did not lead to an
increased yield (entries 1 and 2) provided the temperature was
kept above 30 °C, below which no conversion was observed. In
an attempt to dissociate potential aggregates and activate the
Table 3 Reaction scope of cross-coupling of 9 with different aryl
bromides
Entry R Product Yield of 12a
1 Me 12a 56%
2 OMe 12b 51%
3 CF3 12c 68%
Reaction conditions: 2 eq. of alkenyllithium reagent were added over
20 min to a stirred solution of arylbromide and (pre-oxidized) catalyst
in toluene at 35 °C. a Isolated yield after column chromatography.
Table 4 Synthesis of tamoxifen: catalyst screening
Entry Cat. (5%) NMR yielda







Reaction conditions: 2 eq. of alkenyllithium reagent were added over
20 min to a stirred solution of arylbromide and (pre-oxidized) catalyst
in toluene at 35 °C. a Yield determined by 1H-NMR with 1,1,2,2-tetra-
chloroethane as the internal standard, accompanied by <10% of (E)-
tamoxifen relative to (Z)-tamoxifen. b Isolated yield up to 57%.
c 2.5 mol% of the Pd dimer was used.
Table 5 Optimization of the carbolithiation-cross coupling sequence14
Entry Modificationsa Yieldb
1 Temp 50 °C 60
2 Temp 35 °C 68
3 TMEDA (1 eq.) 25
4 1.3 eq. of 7 65
5 10% cat., 1.3 eq. of 7 65
6 2.5% cat. —
7 2.5% cat.c —
8 BF3 —
9 MgCl2 58
10 Concentrated (1 M)d 54
11 C2e 1.25% cat. 14
12 C3e 1.25% cat. 28
a Reaction conditions: 2 eq. of alkenyllithium reagent were added over
20 min to a stirred solution of arylbromide (2 mmol) and pre-oxidized
catalyst in toluene (2 ml) at room temperature. b Yield determined by
1H-NMR with 1,1,2,2-tetrachloroethane as the internal standard.
cDifferent batches of catalyst. d Initial concentration of arylbromide.
e The complexes C2 and C3 were used with the same Pd concentration
as entries 6 and 7.
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organolithium reagent, TMEDA was added, but this resulted in
a sharp decline in yield (entry 3). The excess of organolithium
reagent could be lowered to 1.3 equivalents without a signifi-
cant loss in yield (entry 4). Further lowering of the catalyst
loading (2.5 mol%) led to an inactive system, with no product
formed (entries 6 and 7). This complete deactivation of the
catalyst at 2.5 mol% has not been observed before, and it is
potentially attributed to the chelating effect of the aminoether
moiety that is present in the substrate. An attempt to prevent
the chelating effect of the aminoether side chain by means of
the addition of Lewis acids such as BF3 or MgCl2 did not prove
beneficial for the reaction (entries 8 and 9). To minimize waste
caused by the solvent, the reaction was performed in a
minimal amount of solvent, with a 1 M concentration, which
only led to a slight decrease in yield (entry 10). Lower loadings
(1.25 mol%) of complexes C2 and C3 provided better conver-
sion than our catalyst of choice at those concentrations
(entries 6, 11 and 12), but still providing lower overall yields
(14% and 28%, respectively).
Having a setup that produces this pharmaceutical com-
pound in good yield and with minimal waste (LiBr being the
only stoichiometric waste in the last step), we compared our
procedure with other (recent) reported syntheses of
tamoxifen6,15–37 focusing on atom economy and Reaction Mass
Efficiency (RME).12b Fig. 3 shows a large range in atom
economy (shown in blue) between different reported syntheses
of tamoxifen. The method described by Larock in 200537 is the
closest to the reported route in this work in terms of atom
economy (48 vs. 67%), but due to a large excess of some
reagents, it scores much lower on RME (shown in red).
With our current setup, by employing commercially avail-
able starting materials, a total atom economy of 0.67 is
achieved, and the resulting RME (22%) is almost twice as high
as that of the runner-up (Knochel, 1997, 11%).20 We believe
that the currently reported methodology presents additional
relevant advantages, since LiBr, NaCl and HCl are the only
stoichiometrically produced waste sources, and the reaction
can be performed at a slightly elevated temperature in a
minimal amount of solvent.
To establish the optimal isolation method, the synthesized
(Z)-tamoxifen was purified by means of crystallization, extrac-
tion, column chromatography and distillation. The excess
organolithium reagent (protonated after reaction quenching,
12-H) and the formed lithium bromide pose no difficulty in
the separation from the product (Fig. 4). Acid–base extraction
and column chromatography were both suitable means to
achieve purification.
The remaining impurity of dehalogenated starting material
13 exhibits near identical behavior compared to the product,
but flash chromatography was able to yield the pure (E/Z)-
tamoxifen mixture. If desired, RP-preparative HPLC in water/
acetonitrile/TFA effectively separates the (E) from the (Z)
isomer of the product.
In conclusion, the carbolithiation of diphenylacetylene and
the consecutive cross-coupling with the appropriate 4-bromo-
dimethylamine-ethylether (6) yields (Z)-tamoxifen with a good
(Z/E) selectivity (10 : 1) and with yields up to 65%. The reaction
mixture was purified by flash chromatography to obtain the
pure (E/Z)-tamoxifen mixture. Further optimization could lead
to a lowering of the catalyst loading and suppression of the
lithium halogen exchange or E–Z isomerisation that lead
to the undesired side products which have proven to be a
challenge in the purification of this pharmaceutical. The
method distinguishes itself from previously reported syntheses
by its high atom economy, reaction mass efficiency, non-toxic
waste production, step count and ease of reaction setup.
The organolithium cross-coupling is also an attractive
strategy for the coupling of less reactive electrophiles
(chlorides, fluorides and ethers)5j and future studies might
further enhance the efficiency towards triarylethylenes and
related products.
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